# LeonaBio, Inc. (LONA)

> Source: Nexqual · https://nexqual.com/LONA · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, LeonaBio, Inc. (LONA), nexqual.com/LONA" · informational, not investment advice.

**Price:** USD 5.29 (-1.86% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 5.39 · day 4.91–5.42 · 52w 2.21–14.21 · market cap $49.8M · NCM

## Key facts
- Analysts: Buy (mean 1.50 on a 1–5 scale) (4 analysts), mean target USD 17.33 (range 15–20).
- Total return with dividends: 1Y +44.5% vs S&P 500 +18.1%; 5Y -94.5% vs S&P 500 +85.1%.
- Next earnings: 2026-08-06, EPS estimate USD -0.69, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.50 on a 1–5 scale), 4 analysts; mean target USD 17.33 (low 15, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | Mizuho | Target lowered | Outperform | $16 → $15 |
| 2026-08-17 | Citizens | Target lowered | Market Outperform | $18 → $17 |
| 2026-07-30 | Citizens | Upgrade | Market Perform → Market Outperform | $18 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +44.5% | -94.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +44.7% | -43.9% |
| Volatility (annualized) | 115.3% | 125.4% |
| Max drawdown | -75.4% (Apr 2026→Sep 2026) | -98.5% (Nov 2021→Apr 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/LONA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt